Show Less

Intellectual Property and Sustainable Development

Development Agendas in a Changing World

  • Elgar Intellectual Property and Global Development series

Edited by Ricardo Meléndez-Ortiz and Pedro Roffe

This comprehensive book considers new and emerging IP issues from a development perspective, examining recent trends and developments in this area. Presenting an overview of the IP landscape in general, the contributing authors subsequently narrow their focus, providing wide-ranging case studies from countries across Africa, Asia and Latin America on topical issues in the current IP discourse. These include the impact of IP on the pharmaceutical sector, the protection of life forms and traditional knowledge, geographical indications, access to knowledge and public research institutes, and the role of competition policy. The challenges developing countries face in the TRIPS-Plus world are also explored in detail.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 5: A Review of the Economic Literature

Keith E. Maskus


Keith E. Maskus INTRODUCTION As a consequence of the WTO TRIPS Agreement, many developing countries have implemented or strengthened product patents in pharmaceuticals in recent years, though the Doha Declaration of 2001 clarified that the least developed WTO Members may delay such implementation or enforcement of drug patents until 2016. The TRIPS Agreement requires the provision of patents across virtually all fields of technology, including pharmaceuticals, for a minimum of 20 years. It also sets out restrictive conditions under which compulsory licences may be issued. The agreement is silent on geographical exhaustion of rights (thereby leaving it to each country whether to permit parallel trade) and whether governments may allow a research exception from the patent-use exclusive rights. Lastly, while requiring protection of confidential test data, the TRIPS Agreement does not prescribe terms or a minimum period of protection. In short, TRIPS retains a number of provisions under which governments in developing countries may reasonably use regulatory authority to limit the scope of drug patents. Discontented with this degree of protection, the European Union and, particularly, the United States, have increasingly demanded intellectual property protection in pharmaceuticals that go beyond TRIPS (so-called ‘TRIPS-Plus’ standards) in bilateral trade agreement negotiations with developing nations. These latter standards involve, inter alia, virtually abandoning recourse to compulsory licensing, restricting parallel importation, the recognition of extension or continuation patents, and lengthy periods of confidentiality for clinical trials test data.1 These provisions are designed to slow down considerably the entry of generic competitors in patented pharmaceutical...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.